Experimental combo therapy targets Hard-to-Treat HER2+ cancers
NCT ID NCT06027983
First seen Nov 01, 2025 · Last updated Apr 26, 2026 · Updated 19 times
Summary
This early-phase study tests whether combining trastuzumab (a targeted antibody) with a patient's own engineered immune cells (CAR T cells) is safe and feasible for people with HER2-positive advanced breast cancer and other solid tumors. The trial enrolls 36 adults aged 21 and older. The goal is to see if this combination can control the disease, but it is not expected to be a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OTHER SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.